talipexole
Sign in to saveAlso known as B-HT920, BHT920
Talipexole (B-HT920, Domnin) is a dopamine agonist that is marketed as a treatment for Parkinson's disease in Japan by Boehringer Ingelheim; it was introduced in 1996. As of December 2014 it was not approved for marketing in the US nor in Europe.
~1 min read
Encyclopedic overview
3 sectionsContents
- Synthesis
- See also
- References
Talipexole (B-HT920, Domnin) is a dopamine agonist that is marketed as a treatment for Parkinson's disease in Japan by Boehringer Ingelheim; it was introduced in 1996. As of December 2014 it was not approved for marketing in the US nor in Europe.
Talipexole is a dopamine D2 receptor agonist and interacts with both pre- and post-synaptic receptors. It also is an α2-adrenergic agonist.
Excerpted from Wikipedia’s “talipexole” article, available under the CC BY-SA 4.0 licence.